← Leaderboards
Barbara J Gitlitz
University Of California Los Angeles
$1,315,824
Attributed
$1,315,824
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,315,824 · 3
By mechanism
M01$829,064 · 2
K23$486,760 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Scott G Kitchen$17,099,191
- Yvonne J Bryson$45,728,199
- Steven Grant Deeks$52,964,444
- Yousang Gwack$8,487,612
- Theodoros Kelesidis$4,316,026
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchNeoplasm /Cancer VaccineDrug Screening /EvaluationHuman SubjectHuman Therapy EvaluationClinical Trial Phase INeoplasm /Cancer ImmunotherapyInterleukin 2Dendritic CellsProstate NeoplasmsInterleukin 4Colony Stimulating FactorVector VaccineLung NeoplasmsMetastasisMucinsVaccinia VirusActive ImmunizationRenal Cell CarcinomaClinical Trial Phase IiVaccine Evaluation
Grant awards (8)
IN VIVO GENERATED DENDRITIC CELL BASED IMMUNOTHERAPY$121,770
K23 · FY2004 · RR
IN VIVO GENERATED DENDRITIC CELL BASED IMMUNOTHERAPY$121,770
K23 · FY2003 · RR
IN VIVO GENERATED DENDRITIC CELL BASED IMMUNOTHERAPY$121,770
K23 · FY2002 · RR
ANTIGEN SPECIFIC IMMUNOTHERAPY IN MUC 1 POSITIVE PATIENTS W/ LUNG CANCER$207,266
M01 · FY2001 · RR
ANTIGEN SPECIFIC IMMUNOTHERAPY IN MUC 1 POSITIVE PATIENTS W/ LUNG CANCER$207,266
M01 · FY2001 · RR
PHASE I PILOT TRIAL OF DENDRITIC CELL VACCINE IN METASTATIC RENAL CELL CARCINOMA$207,266
M01 · FY2001 · RR
PHASE I PILOT TRIAL OF DENDRITIC CELL VACCINE IN METASTATIC RENAL CELL CARCINOMA$207,266
M01 · FY2001 · RR
IN VIVO GENERATED DENDRITIC CELL BASED IMMUNOTHERAPY$121,450
K23 · FY2001 · RR